European Hematology Association Congress | Conference

CTL019 CAR T-Cell Therapy Strides Towards Approval in Pediatric and Young Adult Patients With ALL

June 25th 2017

CTL019, an investigational chimeric antigen receptor T-cell therapy, demonstrated high response rates and a manageable safety profile in pediatric and young adult patients with relapsed and/or refractory acute lymphoblastic leukemia.

Dr. Wang Discusses FLT3 Mutations in AML

June 25th 2017

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses FLT3 mutations in acute myeloid leukemia.

Dr. Perales on Remaining Questions With CAR T-Cell Therapy in Hematologic Malignancies

June 24th 2017

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses the remaining questions with CAR T-cell therapy in hematologic malignancies.

Dr. Eskelund on Study of TP53 Mutations in Mantle Cell Lymphoma

June 24th 2017

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses a study of TP53 mutations in mantle cell lymphoma.

Cerdulatinib Shows Promise in Relapsed/Refractory NHL

June 24th 2017

Paul A. Hamlin, MD, discusses his research with cerdulatinib in patients with certain types of non-Hodgkin lymphoma.

Comparison of Induction Therapies Prior to ASCT Favors Novel Quadruple Over Triplet Regimens

June 24th 2017

Results from the phase III Myeloma XI study showed that patients with myeloma had deeper responses after induction and after allo-stem cell transplantation with outpatient-delivered quadruplet therapy than with sequential immunomodulatory triplet combinations.

Ixazomib Maintenance Shows Robust Activity in Multiple Myeloma

June 24th 2017

Patients with newly-diagnosed multiple myeloma who did not elect to undergo stem cell transplant but remained on single agent ixazomib maintenance fared as well as those who received SCT.

Dr. Hiddemann on Updated Results of Immunochemotherapy Study in Follicular Lymphoma

June 24th 2017

Wolfgang Hiddemann, MD, PhD, director of the Department of Hematology and Oncology, University of Munich, discusses the updated results of an immunochemotherapy study in follicular lymphoma.

Dr. Hamlin on Study of Cerdulatinib in Non-Hodgkin Lymphoma

June 24th 2017

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

Response Rate Hits 100% for bb2121 in Multiple Myeloma

June 23rd 2017

All patients with multiple myeloma in a phase I study showed a response following treatment with an active dose of bb2121, an investigational anti–BCMA CAR T-cell construct.

Biomarkers Emerge for Severe Neurotoxicity Risk After CAR T-Cell Therapy

June 23rd 2017

Investigators reported the characterization of early clinical and serum biomarkers that may identify specific patients with ALL being treated with 19-28z chimeric antigen receptor T cells needing an early intervention to mitigate the development of severe neurotoxicity.

Beyond Midostaurin: Advances Continue With FLT3 Inhibitors in AML

June 23rd 2017

Jorge E. Cortes, MD, discusses ongoing advances with FLT3 inhibitors in acute myeloid leukemia.

Dr. Cortes Discusses FLT3 Inhibitors in AML

June 22nd 2017

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses FLT3 Inhibitors in acute myeloid leukemia.

Martin Moorhead on Role of Minimal Residual Disease in Leukemia and Lymphoma

July 29th 2016

Dr. Raoul Tibes Discusses FLT3 Inhibitors in AML

July 29th 2016

Dr. Max Topp on the TOWER study and Blinatumomab in ALL

July 28th 2016

Dr. Stephanie Goff on Low-Dose Chemotherapy with CAR T-Cells in Advanced Lymphoma

July 27th 2016

Dr. Igor Aurer on Novel Treatments on the Horizon in Hodgkin Lymphoma

July 27th 2016

Dr. DeAngelo on Inotuzumab Ozogamicin for Relapsed/Refractory ALL

July 26th 2016

Dr. Francesco Forconi on B-cell Receptor Structure and Function in CLL

July 6th 2016

Francesco Forconi, MD, associate professor of Hematology, University of Southampton, United Kingdom, discusses the role of the B-cell receptor (BCR) in chronic lymphocytic leukemia (CLL).